16-3 China approves recombinant subunit COVID vaccine

China approved a recombinant protein subunit vaccine against COVID-19 for emergency use. The vaccine was developed by the CAS Institute of Microbiology and Anhui Zhifei Longcom and is manufactured using CHO cells. It is the fourth vaccine approved in China for emergency use against COVID-19. It is currently in phase III clinical trials in Uzbekistan, Pakistan, Ecuador and Indonesia, with plans to inoculate a total of 29,000 volunteers.

China Daily, March 16, 2021

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny